BUSINESS BRIEFING
Times Wire Reports
Amgen Inc. said its cancer drug Vectibix was effective for advanced colon cancer patients as a second-line therapy, a finding consistent with results released Aug. 6 for the therapy as an initial treatment.
A study found that Vectibix “significantly improved” the time before symptoms worsened in advanced colon cancer patients with a certain gene mutation, the Thousand Oaks company said.
